The consensus among analysts is that Onconova Therapeutics, Inc. (ONTX) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 4 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.03.
Onconova Therapeutics, Inc. (NASDAQ:ONTX) trade information
Sporting 4.53% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Jun 23 when the ONTX stock price touched $0.64 or saw a rise of 11.63%. Year-to-date, Onconova Therapeutics, Inc. shares have moved 47.68%, while the 5-day performance has seen it change -7.93%. Over the past 30 days, the shares of Onconova Therapeutics, Inc. (NASDAQ:ONTX) have changed 35.44%. Short interest in the company has seen 6.37 Million shares shorted with days to cover at 0.62.
Onconova Therapeutics, Inc. (ONTX) estimates and forecasts
Figures show that Onconova Therapeutics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +36.62% over the past 6 months, with this year growth rate of -91.28%, compared to 12.4% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 95% and 96% for the next quarter. Revenue growth from the last financial year stood is estimated to be +41.5%.
3 analysts offering their estimates for the company have set an average revenue estimate of $170Million for the current quarter. 3 have an estimated revenue figure of $1.41 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $2Million for this quarter, and analysts expect sales will grow by -91.5% for the current quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +67.9% over the past 5 years. Earnings growth for 2020 is a modest +70% while over the next 5 years, the company’s earnings are expected to increase by 0%.